positioning the company as a leader in personalized dietary solutions for IBS. 67.1% of patients with constipation-predominant IBS (IBS-C) and 66% with mixed IBS (IBS-M) in the treatment group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results